Hostname: page-component-848d4c4894-4rdrl Total loading time: 0 Render date: 2024-06-19T00:05:42.342Z Has data issue: false hasContentIssue false
  • English
  • Français

Neurofarmagen® Testing and Drug Side Effects: An Evaluation of its Use Among a Real-world Case Series

Published online by Cambridge University Press:  23 March 2020

F. Oliva ,
A. Portigliatti Pomeri ,
G. Nibbio  and
M. Giuseppe
F. Oliva*
Affiliation:
University of Turin, Department of Biological and Clinical Sciences, Orbassano, TO, Italy
A. Portigliatti Pomeri
Affiliation:
University of Turin, Department of Neurosciences “Rita Levi Montalcini”, Orbassano, TO, Italy
G. Nibbio
Affiliation:
University of Turin, Department Biological and Clinical Sciences, Orbassano, TO, Italy
M. Giuseppe
Affiliation:
University of Turin, Department of Neurosciences “Rita Levi Montalcini”, Orbassano, TO, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Various pharmacokinetic and pharmacodynamics features have proven to be involved in the development of drug-induced side effects in psychiatry and thus pharmacogenetic profiling should be considered during drug selection to avoid the onset of side effects.

Aim

To explore the usefulness of Neurofarmagen® testing in clinical practice by evaluating whether the genetic profile given by the tool could properly explain the onset of side effects during antipsychotic treatment.

Methods

The pharmacogenetic profile of ten patients having a history of side effect appeared during to specific a psychopharmacologic treatment was determined by Neurofarmagen® testing tool. The relationship between genetic profile and side effects was evaluated and classified.

Results

Sixty percent of the sample showed a genomic alteration related to a increased likelihood of having any side effects, one half of which presented pharmacokinetic alteration (slow or intermediate phenotype for the implicated cytochrome) whereas the other half had a pharmacodynamic gene variant (related to dopamine or serotonin pathway).

Conclusion

the Neurofarmagen® testing tool may be useful in the clinical practice in order to avoid drug-induced side effects.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV712
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S466
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.